Calendario de promoción Belite Bio, Inc
Horario avanzado
gráfico sencillo
Acerca de la empresa Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. más detalles| IPO date | 2022-04-29 |
|---|---|
| ISIN | US07782B1044 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://belitebio.com |
| Цена ао | 67.55 |
| Cambio de precio por día: | -1.51% (62.95) |
|---|---|
| Cambio de precio por semana.: | -3.31% (64.12) |
| Cambio de precio por mes: | -8.07% (67.44) |
| Cambio de precio en 3 meses.: | +33.19% (46.55) |
| Cambio de precio en seis meses: | +36.26% (45.5) |
| Cambio de precio por año: | +35.52% (45.75) |
| Cambio de precio desde principios de año.: | -3.16% (64.02) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| Armistice Capital, LLC | 36000 | 0.12 |
| Morgan Stanley | 22421 | 0.08 |
| State Street Corporation | 17557 | 0.06 |
| Cubist Systematic Strategies, LLC | 16882 | 0.06 |
| Marshall Wace LLP | 16011 | 0.05 |
| JP Morgan Chase & Company | 14267 | 0.05 |
| Point72 Asset Management, L.P. | 7700 | 0.03 |
| Geode Capital Management, LLC | 6700 | 0.02 |
| Jump Financial, LLC | 5200 | 0.02 |
| Renaissance Technologies, LLC | 4900 | 0.02 |
| ETF | Compartir, % | Rentabilidad del año, % | Dividendos, % |
|---|---|---|---|
| Virtus LifeSci Biotech Clinical Trials ETF | 0.76712 | 63.04 | 0.33 |
| SPDR S&P Emerging Markets Small Cap ETF | 0.03878 | 5.46 | 3.03583 |
SPDR S&P China ETF
|
0.02029 | 17.02 | 3.40103 |
| SPDR Portfolio Emerging Markets ETF | 0.00475 | 11.59 | 3.1879 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & CEO | N/A | 1979 (46 años) |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | CFO & Director | N/A | 1985 (40 años) |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer | N/A | 1967 (58 años) |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board |
DIRECCIÓN: United States, San Diego. CA, 12750 High Bluff Drive - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://belitebio.com
Sitio web: https://belitebio.com
